Home From Drew Altman

From Drew Altman

Drew Altman is president and chief executive officer of KFF, a position he has held for more than 30 years since founding the modern-day KFF organization in the 1990s. He is a leading expert on national health policy issues and an innovator in health journalism and the nonprofit field.

View full bio | Read Dr. Altman's Beyond the Data columns

Photo of Drew Altman

President’s Message

“KFF is an independent source of health policy research, polling, and journalism. We have three major program areas: KFF Policy; KFF Polling; and KFF Health News (formerly Kaiser Health News), which conducts specialized public health information campaigns. Learn more about the organization. 

What’s unique about KFF, however, can’t be found in any description of our programs because we’re more than a sum of our parts. KFF is a one-of-a-kind information organization. Not a policy research organization. Not a polling organization. And not a news organization. But rather, a unique combination of all three. That’s the vision behind KFF, and it's this combination that allows us to leverage our combined expertise and assets to play our national role on health policy.” Read more

Beyond the Data

In his “Beyond the Data” columns, Drew Altman discusses what the data, polls, and journalism produced by KFF mean for policy and for people.

There Are Many MAHAs

In a new column, Dr. Drew Altman, Founding President and CEO, dissects the MAHA “movement.” He writes: “There appear to be many MAHAs, not one. You can care about pesticides, or food additives, or vaccines, or child health, or corporate influence, or all of the above, to varying degrees. The reason so many Americans say they support MAHA when asked in polls is that, like a restaurant with a large menu, there is something in it for many Americans to select. But, the one thing they care about most—their health care costs—isn’t on the menu.”

View All Beyond the Data Columns

View the Latest: From Drew Altman

Filter

List Grid

71 - 80 of 341 Results

  • Persistent Vaccine Myths

    From Drew Altman

    With news that the country has now vaccinated half of its population with at least one dose, This Drew Altman Axios column highlights the persistent COVID-19 vaccine myths that are believed by a substantial portion of the unvaccinated population and discusses the options to address vaccine misinformation.

  • Corporate Leaders Are Getting Bullish On Government Action On Health Care Costs

    From Drew Altman

    In this Axios column, Drew Altman explores whether the long struggle with rising health costs has caused the tide to turn in corporate leaders’ attitudes towards government involvement in controlling health spending and whether it is part of a larger shift in comfort with government action to solve problems.

  • Where To Start To Build Vaccine Confidence

    From Drew Altman

    In this Axios column Drew Altman writes about the recent attention to Republican vaccine resisters. “Republicans and rural Americans are among the most resistant vaccine holdouts and some strategies are emerging to reach them." But “far from all Republicans are resisters” and “the bigger and quicker payoff will come from prioritizing the more moveable group of 'wait and see' Americans.”

  • Vaccine Confidence Isn’t The Main Obstacle To Reaching Herd Immunity

    From Drew Altman

    In this Axios column, Drew Altman paints a more optimistic picture of the prospects for getting to herd immunity as vaccine confidence grows, but underscores the urgency of building vaccine confidence in Black and Latino communities where barriers to access and good information are obstacles to getting vaccinated.

  • Seeing Others Vaccinated May Be The Best Cure For Vaccine Hesitancy

    From Drew Altman

    In his latest Axios column, Drew Altman shows why vaccine hesitancy will naturally decrease as more and more people see their family members and friends vaccinated without adverse consequences. It’s a hopeful sign about vaccine hesitancy, and should help free up resources to focus on the remaining vaccine hesitant.